Effect of Humanin treatment on brain tumor vascular cells
Ontology highlight
ABSTRACT:
PROVIDER: PRJEB75574 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| ERR13071500_1.fastq.gz | Fastqsanger.gz | |||
| ERR13071500_2.fastq.gz | Fastqsanger.gz | |||
| ERR13071501_1.fastq.gz | Fastqsanger.gz | |||
| ERR13071501_2.fastq.gz | Fastqsanger.gz | |||
| ERR13071502_1.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 22 |
Similar Datasets
Project description:Effect of Humanin treatment on brain tumor cell lines
| PRJEB64793 | ENA
Project description:Aggressive brain tumors often exhibit immunologically ‘cold’ microenvironment, where the vascular barrier impedes effective immunotherapy in poorly understood ways. Tumor vasculature also plays a pivotal role in immunoregulation and antitumor immunity. Here we show that small GTPase Rab27 controls the vascular morphogenesis and permeability for blood content and immune effectors. Thus, in Rab27a/b double knock out (Rab27-dKO) mice, the brain vasculature is abnormally scarce while the blood vessels become dysmorphic and hyperpermeable in the context of brain tumors, including syngeneic glioblastoma. These defects are reflected in rearrangements of endothelial cell subpopulations with underlying diminution of venous endothelial subtype along with changes in gene and protein expression. Notably, Rab27-dKO brain endothelial cells exhibit deficient tight junctions, whereby they enable large-scale extravasation of cytotoxic T cells into the tumor mass. We show that Rab27-regulated vascular T cell infiltration can be exploited to enhance adoptive T cell therapy in syngeneic brain tumors.
2025-06-02 | PXD062939 | Pride
Project description:RNA sequencing analysis was performed on at least 1000 tumor-derived bulk-sorted mouse cells. Quality control of total RNA samples after RNA isolation with the Agilent Bioanalyzer revealed acceptable RNA quality for provided samples. Libraries were successfully prepared from these RNA samples using the Illumina TruSeq® Stranded mRNA technology. This approach uses fragmentation and sequencing adapter ligation in combination with a poly-T oligo pulldown. RNA sequencing was performed on the Illumina NextSeq500 next generation sequencing system (Illumina) and its high output mode with two runs of 1x150 bp single-end read chemistry and a high amount of high quality reads was generated.
2024-07-15 | E-MTAB-14064 | biostudies-arrayexpress
Project description:The blood-brain barrier (BBB) plays important roles in brain tumor pathogenesis and treatment response, yet our understanding of its function and heterogeneity within or across brain tumor types remains poorly characterized. Here we analyze the neurovascular unit (NVU) of pediatric high-grade glioma (pHGG) and diffuse midline glioma (DMG) using patient derived xenografts and natively forming glioma mouse models. We show tumor-associated vascular differences between these glioma subtypes, and parallels between PDX and mouse model systems, with DMG models maintaining a more normal vascular architecture, BBB function and endothelial transcriptional program relative to pHGG models. Unlike prior work in angiogenic brain tumors, we find that expression of secreted Wnt antagonists do not alter the tumor-associated vascular phenotype in DMG tumor models. Together, these findings highlight vascular heterogeneity between pHGG and DMG and differences in their response to alterations in developmental BBB signals that may participate in driving these pathological differences.
2021-09-01 | GSE179372 | GEO
Project description:Previous studies showed that S100A8 and S100A9 are involved in neovascularization as well as in tumor development. At high concentrations, S100A8 and S100A9 cause inflammatory response or apoptosis mediated damage in vascular endothelial cells. But the effect of low concentrations of such proteins on endothelial cells remains unknown. This assay was performed to screen for genes that are involved in the response of Human Unbilican Vascular Endothelial Cells to low concentrations of S100A8. Human Umblical Vascular Endothelial Cells (HUVEC) were cultuered and treated with 10ug/mL S100A8 proteins for 4 or 24 hours. Gene profiling was carried out using two-color microarray. Two-condition experiment, S100A8 treatment vs. non-treatment. Two time points: 4 hours and 24 hours. Biological replicates at each time point: 3 control replicates, 3 treatment replicates.
2011-11-20 | E-GEOD-33768 | biostudies-arrayexpress
Project description:The paper describes a model of brain tumor.
Created by COPASI 4.25 (Build 207)
This model is described in the article:
Mathematical model of brain tumour with glia-neuron interactions and chemotherapy treatment
Kelly C. Iarosz, Fernando S. Borges, Antonio M. Batista, Murilo S. Baptista, Regiane A. N. Siqueira, Ricardo L. Viana, Sergio R. Lopes
Abstract:
In recent years, it became clear that a better understanding of the interactions among the main elements involved in the cancer network is necessary for the treatment of cancer and the suppression of cancer growth. In this work we propose a system of coupled differential equations that model brain tumour under treatment by chemotherapy, which considers interactions among the glial cells, the glioma, the neurons, and the chemotherapeutic agents. We study the conditions for the glioma growth to be eliminated, and identify values of the parameters for which the inhibition of the glioma growth is obtained with a minimal loss of healthy cells.
To cite BioModels Database, please use: BioModels Database: An enhanced, curated and annotated resource for published quantitative kinetic models .
To the extent possible under law, all copyright and related or neighbouring rights to this encoded model have been dedicated to the public domain worldwide.
Please refer to CC0 Public Domain Dedication for more information.
2024-09-02 | BIOMD0000000775 | BioModels
Project description:Effect of glutamine treatment on human brain microvascular endothelial cells
| PRJNA1081456 | ENA
Project description:Effect of VEGF-C treatment on sorted brain microglia/macrophages
| PRJNA1061529 | ENA
Project description:Effect of iron exposure on the gene expression profile of human brain vascular pericytes.
| PRJNA957794 | ENA
Project description:Tumors in brain are hype-angiogenic and the anti-vascular therapies are important for the treatment of non-small cell lung carcinoma (NSCLC) derived brain metastasis (BM). Targeting vascular endothelial growth factor (VEGF) and its receptor (VEGFR) is the most effective way of resisting angiogenesis. However, the most widely-used anti-vascular drug (Bevacizumab, Bev) has limited therapeutic effects on NSCLC BM. Here, we defined the overexpression of CD146 and its potent pro-angiogenesis role in NSCLC BM in clinical samples, animal models and ex vivo bionic microfluidic chips. Mechanistically, CD146 exerts a comprehensive and sustained reinforcing effect on the pro-angiogenic VEGF-VEGFR2 axis on the one hand by up-regulating tumoral VEGF transcription and on the other hand by amplifying and sensitizing the VEGFR on endothelial cell as a co-receptor. By revealing the underlying mechanism by which CD146 upregulated in BM that the reactive astrocyte-derived growth arrest specific 6 (GAS6) induces the transcription of CD146 by activating AXL signaling, we demonstrated Bemcentinib (R428/BGB324), an AXL inhibitor, effectively suppressed the CD146 expression in BM cells and exhibited superior anti-vascular efficacy against brain metastases when used alone and in combination with Bev in vivo, providing novel anti-vascular strategies in BM.
2023-11-30 | PXD047390 |